The kits, marketed through US global health firm Abbott, will be the intellectual property of Axis-Shield until 2024.
The firm hopes its technology will replace the current routine blood-testing for vitamin B12 levels in patients.
Advertisement
Hide AdAdvertisement
Hide AdA spokesman for Axis-Shield, whose shares lifted 3.25p to 405p, declined to divulge sales or value figures for the kit, but said they were "gaining ground" on conventional blood tests for vitamin B12 deficiency.
Vitamin B12 deficiency is often a reason for patients showing symptoms of anaemia and neurological problems.